Biblio
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematol. 2020.
First line treatments in primary central nervous system lymphomas in young patients. Curr Opin Oncol. 2023.
.